Quantum BioPharma Announces Debt Settlement, Equity Grants, and Advisor Departure
TL;DR
Quantum BioPharma settles debt with shares and grants RSUs tied to Lucid MS milestones, potentially enhancing financial stability and aligning expert incentives with regulatory success.
Quantum BioPharma issued 1,102 Class B shares at $24.33 each to settle $26,812.50 debt and granted 800 RSUs each to two advisors with milestone-based vesting.
Quantum BioPharma's focus on neurodegenerative and metabolic disorders advances treatments that could improve quality of life for patients with conditions like multiple sclerosis.
Quantum BioPharma's Lucid-MS compound reverses myelin degradation in preclinical models, offering a novel approach to treating multiple sclerosis and related disorders.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantum BioPharma Ltd. (NASDAQ: QNTM) has announced several corporate actions that demonstrate the company's ongoing financial and strategic management during its drug development phase. The biopharmaceutical company, which focuses on treatments for neurodegenerative, metabolic and alcohol misuse disorders, reported that its board approved the settlement of $26,812.50 in outstanding debt through the issuance of 1,102 Class B shares at a deemed price of $24.33 per share on August 12, 2025.
The company also disclosed that on August 15, 2025, the board granted 800 restricted share units each to clinical advisors Peter Stys and Jack Antel under the equity incentive plan. These RSUs have vesting conditions tied to regulatory milestones for the company's Lucid MS program, aligning advisor compensation with the successful development of their lead compound. Both the creditor shares and RSUs are subject to a four-month-plus-one-day statutory hold under CSE policy and are not registered under the U.S. Securities Act.
In a separate development, Quantum BioPharma announced that effective August 15, 2025, Kevin Malone is no longer serving as an advisor to the board following termination of his agreement. This change in advisory structure comes as the company continues to advance its portfolio of innovative assets and biotech solutions.
The company's lead compound, Lucid-MS, represents a significant advancement in multiple sclerosis treatment research. As a patented new chemical entity, Lucid-MS has demonstrated the ability to prevent and reverse myelin degradation in preclinical models, addressing the underlying mechanism of multiple sclerosis. This development through the company's wholly owned subsidiary, Lucid Psycheceuticals Inc., positions Quantum BioPharma in the competitive neurodegenerative treatment market.
Quantum BioPharma maintains additional revenue streams through its ownership stake in Celly Nutrition Corp., which markets the OTC version of UNBUZZD™. The company retains 25.71% ownership of Celly Nutrition as of June 30, 2024, and receives royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company also maintains full rights to develop similar products for pharmaceutical and medical uses. Additional information about the company's investment portfolio is available through its subsidiary FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. Investors can access the latest news and updates relating to QNTM in the company's newsroom at https://ibn.fm/QNTM.
Curated from InvestorBrandNetwork (IBN)
